Updated June 2026 · USPTO PatentsView
When Does Enbrel Patent Expire?
Enbrel appears in the USPTO records tracked here, but no active expiration dates are currently on file — typically meaning composition-of-matter patents have already lapsed. Generic or biosimilar competitors may already be available; check the FDA Orange Book for the current Paragraph IV-eligible patent listing.
Enbrel Patent Snapshot
| Total US Patents | 0 |
| Earliest Patent Expiration | N/A |
| Latest Patent Expiration | N/A |
| Years Until First Expiry | Already expired |
| Patent Holders | Amgen Inc., Pfizer Inc. |
| Generic Name | etanercept |
| Patent Strength Score | F0/100 |
When the Enbrel Patent Cliff Hits
Expiration dates for Enbrel are not yet on file in the USPTO records aggregated here, which usually means the patents have already lapsed or the data set has not yet propagated. Generic equivalents may already be available.
Without a clean earliest-expiration date on record, the safest signal for generic availability is the FDA Orange Book, which lists patents that ANDA filers must address. If no patents appear in the Orange Book listing for Enbrel, generics may already be approvable.
For the authoritative listing of patents tied to a specific drug — the patents an ANDA filer is legally required to address under 21 USC § 355(j) — consult the FDA Orange Book. Underlying utility patent data on this page is sourced from USPTO PatentsView, the federal government's free public patent API.
Inside the Enbrel Patent Portfolio
No active US patents are currently associated with Enbrel in the USPTO records used here. That can mean the drug's primary composition patents have already expired, that protection is held under different naming conventions, or that exclusivity is now maintained through FDA-granted regulatory pathways (NCE, orphan, pediatric) rather than patents.
Enbrel patent rights are held across 2 entities: Amgen Inc., Pfizer Inc.. Multi-assignee portfolios usually reflect co-development partnerships, licensing splits between an originator and a marketing partner, or assignments made during corporate restructurings. Multi-party ownership can complicate generic entry — a challenger may need to clear patents from each holder separately, and settlements are harder to reach.
The Enbrel portfolio scores 0/100 (Grade F, "very weak") on the PatentCliff Strength index. The strongest signal is portfolio size (0/100), and the weakest is portfolio size (0/100). The four factors are weighted by how well they predict real-world resilience to generic challenge: portfolio size 30%, claims breadth 25%, time remaining 25%, and technology diversity 20%.
Enbrel vs Other Branded Drugs
Enbrel's 0-patent portfolio is 100% smaller than the average drug tracked here (8 patents) — lighter-than-typical lifecycle protection. Among the 40 drugs in this database, Enbrel ranks #26 by patent count. For broader context, the earliest expiration in the data set is Ozempic (2026) and the longest-protected drug is Mounjaro (latest expiry 2041).
Expiration Timeline
The 20-year patent term in the United States runs from the earliest non-provisional filing date, not the grant date. That means a patent granted in 2015 from a 2010 filing has only 15 years of life left at grant — a feature of US patent law that creates the layered "cliff" pattern visible in most branded drug portfolios. Patent Term Extension under 35 USC § 156 can add up to 5 years for time lost to FDA review, and pediatric exclusivity can add 6 months on top.
How the Patent Strength Score Is Calculated
The PatentCliff Strength Score combines four signals from USPTO data into a single 0-100 grade. Portfolio size (30%) measures the number of patents covering the drug — a proxy for litigation depth and the count of independent challenges a generic must clear. Claims breadth (25%) is the average number of claims per patent, an indicator of how broadly each patent attempts to cover the underlying invention. Time remaining (25%) measures average years until expiration across the portfolio. Technology diversity (20%) measures the number of distinct CPC (Cooperative Patent Classification) classes the portfolio touches — diverse portfolios are harder to design around. Read the full PatentCliff methodology, including how scores compare to citation-weighted academic measures.
Related Questions About Enbrel
Sources: Patent records — USPTO PatentsView API (public domain). Drug-to-patent mapping cross-referenced against the FDA Orange Book. Expiration dates calculated as application date plus 20 years per 35 USC § 154.
Cite as: "PatentCliff, June 2026 reading. Source: USPTO PatentsView." Last updated 2026-06-24.
This answer pulls from the FDA Orange Book and USPTO patent records, the authoritative federal source for U.S. pharmaceutical patent expirations. The headline number above is the direct answer; what follows is the additional context most readers need to use the answer for a real decision rather than just a fact lookup.
A practical caveat: the headline answer above reflects the most recent the FDA Orange Book and USPTO patent records vintage; underlying data is often revised for months after first publication, and the right reference for any specific decision is whichever vintage is current at the time of the decision. The as-of date is stamped on every page.